STOCK TITAN
  1. Home
  2. News
  3. TELA

TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the JMP Securities Life Sciences Conference.

TELA Bio's management is scheduled to present at the JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:30 AM EDT. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.

TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
347-620-7010 
ir@telabio.com


Stock TELA logo
TELA Bio, Inc.

NASDAQ:TELA

TELA Rankings

#4170 Ranked by Market Cap
#4091 Ranked by Stock Gains
N/A Ranked by Dividends

TELA Latest News

Apr 25, 2024
TELA Bio to Announce First Quarter 2024 Financial Results
Apr 15, 2024
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
Apr 8, 2024
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Mar 21, 2024
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
Mar 21, 2024
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

TELA Stock Data

116.37M
15.79M
2.54%
86.87%
3.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MALVERN

About TELA

tela bio, inc., a surgical reconstruction company, was created out of the desire to do things differently. combining the drive and innovation of a start-up with a seasoned medical technology team, the company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. based in malvern, pennsylvania, this science-driven company is collaborating with leading surgeons to reinvigorate the soft tissue reconstruction market and bring cost-effective solutions to hospitals, surgeons and patients. please see our social media community guidelines at http://bit.ly/1uvcx0l